Brief: Applied Molecular Transport Completes Enrollment Of Phase 2 Lombard Monotherapy Trial Of Oral AMT-101 In Patients With Moderate-To-Severe Ulcerative Colitis

Applied Molecular Transport.

20/09/2022 14:30

Sept 20 (Reuters) - Applied Molecular Transport Inc.
 AMTI.O :
    * APPLIED MOLECULAR TRANSPORT COMPLETES ENROLLMENT OF PHASE
2
LOMBARD MONOTHERAPY TRIAL OF ORAL AMT-101 IN PATIENTS WITH
MODERATE-TO-SEVERE ULCERATIVE COLITIS
    * APPLIED MOLECULAR TRANSPORT COMPLETES ENROLLMENT OF PHASE
2
LOMBARD MONOTHERAPY TRIAL OF ORAL AMT-101 IN PATIENTS WITH
MODERATE-TO-SEVERE ULCERATIVE COLITIS

Source text for Eikon:  ID:nGNXDMvWg 
Further company coverage:  AMTI.O 

 ((Reuters.Briefs@thomsonreuters.com;))